Inhibikase Therapeutics Inc (NASDAQ: IKT) kicked off on Monday, up 13.22% from the previous trading day, before settling in for the closing price of $2.42. Over the past 52 weeks, IKT has traded in a range of $0.80-$3.82.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 49.79%. While this was happening, its average annual earnings per share was recorded 83.89%. With a float of $64.33 million, this company’s outstanding shares have now reached $67.19 million.
Let’s determine the extent of company efficiency that accounts for 8 employees. In terms of profitability, gross margin is 66.98%, operating margin of -23885.06%, and the pretax margin is -23102.15%.
Inhibikase Therapeutics Inc (IKT) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Inhibikase Therapeutics Inc is 4.27%, while institutional ownership is 28.94%. The most recent insider transaction that took place on Oct 21 ’24, was worth 2,000,200. In this transaction Director of this company bought 1,460,000 shares at a rate of $1.37, taking the stock ownership to the 1,460,000 shares. Before that another transaction happened on Oct 21 ’24, when Company’s Director bought 145,000 for $1.37, making the entire transaction worth $198,650. This insider now owns 145,000 shares in total.
Inhibikase Therapeutics Inc (IKT) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported -0.86 earnings per share (EPS), higher than consensus estimate (set at -1.12) by 0.26. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.05 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 83.89% per share during the next fiscal year.
Inhibikase Therapeutics Inc (NASDAQ: IKT) Trading Performance Indicators
Take a look at Inhibikase Therapeutics Inc’s (IKT) current performance indicators. Last quarter, stock had a quick ratio of 2.32. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2301.26.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.93, a number that is poised to hit -0.37 in the next quarter and is forecasted to reach -0.26 in one year’s time.
Technical Analysis of Inhibikase Therapeutics Inc (IKT)
Looking closely at Inhibikase Therapeutics Inc (NASDAQ: IKT), its last 5-days average volume was 0.44 million, which is a jump from its year-to-date volume of 0.19 million. As of the previous 9 days, the stock’s Stochastic %D was 89.73%. Additionally, its Average True Range was 0.26.
During the past 100 days, Inhibikase Therapeutics Inc’s (IKT) raw stochastic average was set at 97.01%, which indicates a significant increase from 96.96% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 118.60% in the past 14 days, which was higher than the 88.15% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.49, while its 200-day Moving Average is $1.77. However, in the short run, Inhibikase Therapeutics Inc’s stock first resistance to watch stands at $2.88. Second resistance stands at $3.01. The third major resistance level sits at $3.24. If the price goes on to break the first support level at $2.52, it is likely to go to the next support level at $2.29. Now, if the price goes above the second support level, the third support stands at $2.16.
Inhibikase Therapeutics Inc (NASDAQ: IKT) Key Stats
The company with the Market Capitalisation of 184.10 million has total of 7,216K Shares Outstanding. Its annual sales at the moment are 260 K in contrast with the sum of -19,030 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -4,960 K.
